Vlado Perkovic's Publications

• IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

  Journal articles

  2023

  Kidney International Reports

• Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.

  Journal articles

  2023

  Kidney Int

• Glucocorticoids for IgA nephropathypro

  Journal articles

  2023

  Kidney International

• Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.

  Journal articles

  2023

  Clin J Am Soc Nephrol

• The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.

  Journal articles

  2023

  Nephrol Dial Transplant

• Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

  Journal articles

  2023

  American Journal of Kidney Diseases

• WCN23-0069 EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THE TESTING TRIAL

  Journal articles

  2023

  Kidney International Reports

• WCN23-0412 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS OVER TIME IN IgA NEPHROPATHY

  Journal articles

  2023

  Kidney International Reports

• WCN23-0574 THE ELLEN MEDICAL DEVICES AFFORDABLE POINT-OF-CARE PERITONEAL DIALYSIS SYSTEM - A PILOT STUDY

  Journal articles

  2023

  Kidney International Reports

• TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL

  Journal articles

  2023

  Journal of the American College of Cardiology

• Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.

  Journal articles

  2023

  Kidney Int Rep

• Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply

  Journal articles

  2022

  The New England journal of medicine

• Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials.

  Journal articles

  2022

  Nephrol Dial Transplant

• Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy

  Journal articles

  2022

  European Heart Journal

• Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice

  Journal articles

  2022

  Heart Lung and Circulation

• Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

  Journal articles

  2022

  Cardiovascular Diabetology

• Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program

  Journal articles

  2022

  Diabetes, Obesity and Metabolism

• Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

  Journal articles

  2022

  The Lancet

• Abstract 12404: Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin

  Journal articles

  2022

  Circulation

• Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis

  Journal articles

  2022

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

  Journal articles

  2022

  Journal of the American College of Cardiology

• Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

  Journal articles

  2022

  Diabetes Care

• Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease

  Journal articles

  2022

  Clinical Pharmacology and Therapeutics

• The ASCEND-ND trial: study design and participant characteristics

  Journal articles

  2022

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association